Kris Famm, a VP of research at GlaxoSmithKline (NYSE:GSK, LON:GSK), sees a bright future for medical devices: speaking at FierceBiotech’s 2016 Executive Summit, he predicted they would move from “a last resort to an early line treatment.” In other words, the next generation of medical devices may replace molecular drugs…...